Qiagen and Astellas Pharma to collaborate on companion diagnostics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

QIAGEN N.V. and Astellas Pharma Inc. will collaborate to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

Two initial projects in the collaboration focus on oncology and aim to pair Qiagen diagnostics with Astellas compounds in early-stage clinical trials: ASP5878, a fibroblast growth factor receptor inhibitor, and ASP8273, an EGFR inhibitor. Financial terms were not disclosed.

The scope of the agreement is not restricted to certain sample types, platforms, indications or biomarkers, giving Astellas access to Qiagen’s assays based on PCR, next generation sequencing and multi-modal testing technologies using liquid and tissue biopsies.

Table of Contents

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login